%0 Journal Article
%T A US payer perspective health economic model assessing value of monitoring disease activity to inform discontinuation and re-initiation of DMT in multiple sclerosis.
%A Jalaleddini K
%A Bermel RA
%A Talente B
%A Weinstein D
%A Qureshi F
%A Rasmussen M
%A Menon S
%A Amarapala M
%A Jordan K
%A Ghoreyshi A
%A McCurdy S
%A Edgeworth M
%J Mult Scler
%V 30
%N 3
%D 2024 Mar 19
%M 38374525
%F 5.855
%R 10.1177/13524585241227372
%X UNASSIGNED: We evaluate the potential clinical and cost impacts of discontinuing disease-modifying therapy (DMT) in people with multiple sclerosis (PwMS) when age-related immunosenescence can reduce DMT efficacy while increasing associated risks.
UNASSIGNED: A Markov model simulated clinical and cost impacts to the patient and payers when a proportion of eligible patients with relapsing remitting multiple sclerosis (RRMS) discontinue DMT. Eligibility was defined as age >55 years, an RRMS diagnosis of >5 years, and no history of relapses for 5 years. Increasing the proportion of eligible patients willing to discontinue therapy was also modeled. Clinical and cost inputs were from published literature.
UNASSIGNED: Difference in EDSS progression between eligible patients who did and did not attempt discontinuation was not significant. After 1 year of eligibility, per-patient costs were $96k lower in the cohort that attempted discontinuation; however a higher proportion of relapses were seen in this group. When the proportion of patients willing to discontinue DMT increased, clinical findings remained consistent while the average cost per patient decreased.
UNASSIGNED: While there are increased clinical and cost benefits as more eligible patients attempt discontinuation, the risk of relapses can increase. Timely disease monitoring is required to manage safe DMT discontinuation.